AstraZeneca Pharma India has unveiled plans to divest its Bengaluru production facility as part of a comprehensive evaluation of its global manufacturing and supply network, confirmed through a regulatory filing.

The company emphasizes its steadfast commitment to facilitating access to cutting-edge medicines in India, aspiring to lead in scientific innovation, specialize in treating unique disease areas, and enhance patient outcomes.

In line with AstraZeneca's ongoing strategic appraisal of its worldwide manufacturing and supply chain, the decision to phase out operations at the Bangalore manufacturing site has been outlined.

Efforts will focus on preparing the facility for sale while actively seeking a buyer capable of functioning as a contract manufacturing organization (CMO) for the company's existing product line manufactured or packaged at this site.

However, this transition is contingent upon securing the requisite statutory approvals, as specified by the pharmaceutical firm.

Acknowledging the potential implications of this transformation, the company underscores its paramount commitment to its workforce and ensuring a seamless supply of medications to meet patient needs during this period of change.

The Bengaluru site holds pivotal significance as one of nine global locations integral to the design, execution, and regulatory oversight of clinical trials.

It actively contributes to monitoring the safety and efficacy of pharmaceutical products throughout their lifecycle.

Established in 1979, AstraZeneca Pharma India, a subsidiary of AstraZeneca Plc headquartered in Bengaluru, has been a cornerstone in the company's operations, aligning with its overarching global objectives.

This strategic repositioning signifies a shift in the company's operational landscape, underlining its proactive approach to refining its global manufacturing network to align with evolving industry dynamics and deliver enhanced healthcare solutions.